Detalhe da pesquisa
1.
Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma.
Future Oncol
; 17(30): 3965-3976, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34287064
2.
Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma.
Future Oncol
; 15(23): 2699-2706, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31282758
3.
Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO.
Transl Lung Cancer Res
; 11(10): 2010-2021, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36386456
4.
Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.
Anticancer Drugs
; 22(6): 519-30, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21637160
5.
The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting.
Hum Vaccin Immunother
; 9(12): 2533-42, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23955093
6.
Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo.
Clin Transl Oncol
; 14(5): 376-81, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22551544
7.
Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial.
Cancer Immunol Immunother
; 56(9): 1397-406, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17273869